T1	PROC 46 95	Estudio multicéntrico, aleatorizado y doble ciego
T2	PROC 113 124	tratamiento
#1	AnnotatorNotes T2	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T3	CHEM 143 155	carboplatino
#2	AnnotatorNotes T3	C0079083; carboplatin; Organic Chemical · Pharmacologic Substance
T4	CHEM 158 168	paclitaxel
#3	AnnotatorNotes T4	C0144576; paclitaxel; Organic Chemical · Pharmacologic Substance
T5	PROC 176 187	tratamiento
#4	AnnotatorNotes T5	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T6	PROC 315 322	tratado
#5	AnnotatorNotes T6	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T7	CHEM 207 219	carboplatino
#6	AnnotatorNotes T7	C0079083; carboplatin; Organic Chemical · Pharmacologic Substance
T8	CHEM 222 232	paclitaxel
#7	AnnotatorNotes T8	C0144576; paclitaxel; Organic Chemical · Pharmacologic Substance
T9	DISO 239 288	cáncer pulmonar no microcítico (CPNM) epidermoide
T10	PROC 358 418	Estudio de fase 3, multicéntrico, aleatorizado y doble ciego
T11	PROC 436 447	tratamiento
#8	AnnotatorNotes T11	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T12	CHEM 466 478	carboplatino
#9	AnnotatorNotes T12	C0079083; carboplatin; Organic Chemical · Pharmacologic Substance
T13	CHEM 481 491	paclitaxel
#10	AnnotatorNotes T13	C0144576; paclitaxel; Organic Chemical · Pharmacologic Substance
T14	PROC 499 510	tratamiento
#11	AnnotatorNotes T14	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T15	PROC 518 525	placebo
#12	AnnotatorNotes T15	C0032042; Placebos; Therapeutic or Preventive Procedure
T16	CHEM 530 542	carboplatino
#13	AnnotatorNotes T16	C0079083; carboplatin; Organic Chemical · Pharmacologic Substance
T17	CHEM 545 555	paclitaxel
#14	AnnotatorNotes T17	C0144576; paclitaxel; Organic Chemical · Pharmacologic Substance
T18	DISO 562 611	cáncer pulmonar no microcítico (CPNM) epidermoide
T19	PROC 638 645	tratado
#15	AnnotatorNotes T19	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T20	DISO 682 731	Cáncer pulmonar no microcítico (CPNM) epidermoide
T21	DISO 870 886	CPNM epidermoide
T22	DISO 963 979	CPNM epidermoide
T23	PROC 1048 1068	resección quirúrgica
#16	AnnotatorNotes T23	C0728940; Excision; Therapeutic or Preventive Procedure
T24	PROC 1072 1084	radioterapia
#17	AnnotatorNotes T24	C1522449; Therapeutic radiology procedure; Therapeutic or Preventive Procedure
T25	DISO 1206 1222	CPNM epidermoide
T26	PROC 1243 1265	tratamiento quirúrgico
#18	AnnotatorNotes T26	C0543467; Operative Surgical Procedures; Therapeutic or Preventive Procedure
T27	PROC 1295 1315	resección quirúrgica
#19	AnnotatorNotes T27	C0728940; Excision; Therapeutic or Preventive Procedure
T28	PROC 1319 1331	radioterapia
#20	AnnotatorNotes T28	C1522449; Therapeutic radiology procedure; Therapeutic or Preventive Procedure
T29	DISO 1387 1393	lesión
#21	AnnotatorNotes T29	C0221198; Lesion; Finding
T30	DISO 1423 1427	CPNM
#22	AnnotatorNotes T30	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T31	DISO 1865 1873	mutación
T32	DISO 1942 1970	mutación L858R en el exón 21
T33	DISO 1543 1560	hipersensibilidad
#23	AnnotatorNotes T33	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding
T34	CHEM 1573 1583	paclitaxel
#24	AnnotatorNotes T34	C0144576; paclitaxel; Organic Chemical · Pharmacologic Substance
T35	CHEM 1594 1602	fármacos
#25	AnnotatorNotes T35	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T36	CHEM 1629 1659	aceite de ricino polietoxilado
T37	CHEM 1661 1670	Cremophor
#26	AnnotatorNotes T37	C0056475; cremophor; Organic Chemical
T38	DISO 1694 1711	hipersensibilidad
#27	AnnotatorNotes T38	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding
T39	DISO 1771 1792	neuropatía periférica
#28	AnnotatorNotes T39	C0031117; Peripheral Neuropathy; Disease or Syndrome
T40	DISO 1829 1848	CPNM no epidermoide
T41	PROC 2050 2074	quimioterapia citotóxica
#29	AnnotatorNotes T41	C0677881; Cytotoxic Chemotherapy; Therapeutic or Preventive Procedure
T42	PROC 2085 2104	quimiorradioterapia
#30	AnnotatorNotes T42	C0436307; Chemoradiotherapy; Therapeutic or Preventive Procedure
T43	DISO 2125 2129	CPNM
#31	AnnotatorNotes T43	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T44	PROC 2139 2174	tratamiento ayudante o neoadyuvante
T45	CHEM 129 138	veliparib
#32	AnnotatorNotes T45	C1958300; veliparib; Organic Chemical · Pharmacologic Substance
T46	PROC 195 202	placebo
#33	AnnotatorNotes T46	C0032042; Placebos; Therapeutic or Preventive Procedure
T47	ANAT 246 254	pulmonar
#34	AnnotatorNotes T47	C0024109; Lung; Body Part, Organ, or Organ Component | C1278908; Entire lung; Body Part, Organ, or Organ Component
T48	ANAT 258 269	microcítico
#35	AnnotatorNotes T48	C1514085; Neoplastic Small Cell; Cell | C1518241; Malignant Small Cell; Cell
T49	DISO 300 311	metastásico
#36	AnnotatorNotes T49	C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T50	CHEM 452 461	veliparib
#37	AnnotatorNotes T50	C1958300; veliparib; Organic Chemical · Pharmacologic Substance
T51	ANAT 569 577	pulmonar
#38	AnnotatorNotes T51	C0024109; Lung; Body Part, Organ, or Organ Component | C1278908; Entire lung; Body Part, Organ, or Organ Component
T52	ANAT 581 592	microcítico
#39	AnnotatorNotes T52	C1514085; Neoplastic Small Cell; Cell | C1518241; Malignant Small Cell; Cell
T53	DISO 623 634	metastásico
#40	AnnotatorNotes T53	C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T54	ANAT 689 697	pulmonar
#41	AnnotatorNotes T54	C0024109; Lung; Body Part, Organ, or Organ Component | C1278908; Entire lung; Body Part, Organ, or Organ Component
T55	ANAT 701 712	microcítico
#42	AnnotatorNotes T55	C1514085; Neoplastic Small Cell; Cell | C1518241; Malignant Small Cell; Cell
T56	DISO 743 754	metastásico
#43	AnnotatorNotes T56	C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T57	DISO 991 1002	metastásico
#44	AnnotatorNotes T57	C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T58	PROC 1445 1447	TC
#45	AnnotatorNotes T58	C0040405; X-Ray Computed Tomography; Diagnostic Procedure
T59	CHEM 1727 1748	compuestos de platino
#46	AnnotatorNotes T59	C3536919; Platinum Compounds; Chemical Viewed Structurally
T60	DISO 1915 1923	deleción
#47	AnnotatorNotes T60	C1442161; Gene Deletion Abnormality; Cell or Molecular Dysfunction
T61	Date 13 17	2013
T62	Neg_cue 255 257	no
T63	Neg_cue 312 314	no
T64	Neg_cue 578 580	no
T65	Neg_cue 635 637	no
T66	Neg_cue 698 700	no
T67	LIVB 784 790	Sujeto
#48	AnnotatorNotes T67	C0681850; Study Subject; Group
T68	Age 791 800	≥ 18 años
T69	Duration 830 842	> 12 semanas
T70	LIVB 849 855	sujeto
#49	AnnotatorNotes T70	C0681850; Study Subject; Group
T71	LIVB 942 948	sujeto
#50	AnnotatorNotes T71	C0681850; Study Subject; Group
T73	Neg_cue 1027 1029	no
T74	Neg_cue 1069 1071	ni
T76	LIVB 1184 1191	sujetos
#51	AnnotatorNotes T76	C0681850; Study Subject; Group
T77	Neg_cue 1270 1272	no
T78	Neg_cue 1316 1318	ni
T79	LIVB 1358 1364	sujeto
#52	AnnotatorNotes T79	C0681850; Study Subject; Group
T80	LIVB 1527 1533	sujeto
#53	AnnotatorNotes T80	C0681850; Study Subject; Group
T81	LIVB 1678 1684	sujeto
#54	AnnotatorNotes T81	C0681850; Study Subject; Group
T82	LIVB 1755 1761	sujeto
#55	AnnotatorNotes T82	C0681850; Study Subject; Group
T83	LIVB 1812 1818	sujeto
#56	AnnotatorNotes T83	C0681850; Study Subject; Group
T85	GENE 1887 1895	gen EGFR
#57	AnnotatorNotes T85	C1414313; EGFR gene; Gene or Genome
T86	GENE 1928 1935	exón 19
#58	AnnotatorNotes T86	C2736990; EGFR gene exon 19; Gene or Genome
T87	GENE 2005 2012	gen ALK
#59	AnnotatorNotes T87	C1332080; ALK gene; Gene or Genome
T88	LIVB 2019 2025	sujeto
#60	AnnotatorNotes T88	C0681850; Study Subject; Group
T89	Neg_cue 2131 2138	excepto
T72	ANAT 1837 1848	epidermoide
#61	AnnotatorNotes T72	C0221910; Squamous Epithelial Cells; Cell
T75	Neg_cue 1834 1836	no
T84	ANAT 600 611	epidermoide
#62	AnnotatorNotes T84	C0221910; Squamous Epithelial Cells; Cell
T90	ANAT 277 288	epidermoide
#63	AnnotatorNotes T90	C0221910; Squamous Epithelial Cells; Cell
T91	ANAT 720 731	epidermoide
#64	AnnotatorNotes T91	C0221910; Squamous Epithelial Cells; Cell
T92	ANAT 875 886	epidermoide
#65	AnnotatorNotes T92	C0221910; Squamous Epithelial Cells; Cell
T93	ANAT 968 979	epidermoide
#66	AnnotatorNotes T93	C0221910; Squamous Epithelial Cells; Cell
T94	ANAT 1211 1222	epidermoide
#67	AnnotatorNotes T94	C0221910; Squamous Epithelial Cells; Cell
T95	PROC 902 935	medios citológicos o histológicos
#68	AnnotatorNotes T95	C1305671; Cytology procedure; Laboratory Procedure + C0344441; Histology Procedure; Laboratory Procedure
A1	Assertion T48 Negated
A2	Assertion T6 Negated
A3	Assertion T52 Negated
A4	Assertion T55 Negated
A5	Assertion T19 Negated
A6	Assertion T23 Negated
A7	Assertion T24 Negated
A8	Assertion T27 Negated
A9	Assertion T28 Negated
A10	Assertion T44 Negated
A11	Assertion T72 Negated
A12	Status T6 History_of
A13	Status T19 History_of
A14	Status T33 History_of
A15	Status T38 History_of
A16	Status T41 History_of
A17	Status T42 History_of
A18	Status T44 History_of
#69	AnnotatorNotes T1	C1096776; Multicenter Study; Research Activity + C0034656; Randomization; Research Activity + C0013072; Double-Blind Method; Research Activity
#70	AnnotatorNotes T36	C0071558; polyethoxylated castor oil; Organic Chemical · Pharmacologic Substance
#71	AnnotatorNotes T10	C0282461; Phase 3 Clinical Trials; Research Activity + C0034656; Randomization; Research Activity + C0013072; Double-Blind Method; Research Activity + C1096776; Multicenter Study; Research Activity
#72	AnnotatorNotes T9	C4509816; Squamous non-small cell lung cancer; Neoplastic Process
#73	AnnotatorNotes T18	C4509816; Squamous non-small cell lung cancer; Neoplastic Process
#74	AnnotatorNotes T20	C4509816; Squamous non-small cell lung cancer; Neoplastic Process
#75	AnnotatorNotes T21	C4509816; Squamous non-small cell lung cancer; Neoplastic Process
#76	AnnotatorNotes T25	C4509816; Squamous non-small cell lung cancer; Neoplastic Process
#77	AnnotatorNotes T40	C4324656; Non-squamous non-small cell lung cancer; Neoplastic Process 
#78	AnnotatorNotes T22	C4509816; Squamous non-small cell lung cancer; Neoplastic Process
#79	AnnotatorNotes T31	C1705285; Mutation Abnormality; Cell or Molecular Dysfunction
#80	AnnotatorNotes T32	C3888903; Point mutation in exon 21 (L858R); Cell or Molecular Dysfunction
#81	AnnotatorNotes T44	C0677850; Adjuvant therapy; Therapeutic or Preventive Procedure + C0600558; Neoadjuvant Therapy; Therapeutic or Preventive Procedure
R1	Negation Arg1:T62 Arg2:T48	
R2	Negation Arg1:T63 Arg2:T6	
R3	Negation Arg1:T65 Arg2:T19	
R4	Negation Arg1:T64 Arg2:T52	
R5	Negation Arg1:T66 Arg2:T55	
R6	Negation Arg1:T73 Arg2:T23	
R7	Negation Arg1:T74 Arg2:T24	
T96	Quantifier_or_Qualifier 1085 1104	con fines curativos
A19	Assertion T96 Negated
R8	Has_Quantifier_or_Qualifier Arg1:T24 Arg2:T96	
R9	Negation Arg1:T74 Arg2:T96	
R10	Negation Arg1:T77 Arg2:T27	
R11	Negation Arg1:T78 Arg2:T28	
T97	Quantifier_or_Qualifier 1332 1351	con fines curativos
A20	Assertion T97 Negated
R12	Has_Quantifier_or_Qualifier Arg1:T28 Arg2:T97	
R13	Negation Arg1:T75 Arg2:T72	
R14	Negation Arg1:T89 Arg2:T44	
R15	Combined_with Arg1:T45 Arg2:T3	
R16	Combined_with Arg1:T3 Arg2:T4	
R17	Used_for Arg1:T45 Arg2:T2	
R18	Used_for Arg1:T46 Arg2:T5	
R19	Combined_with Arg1:T46 Arg2:T7	
R20	Combined_with Arg1:T7 Arg2:T8	
R21	Location_of Arg1:T47 Arg2:T9	
R22	Location_of Arg1:T90 Arg2:T9	
R23	Before Arg1:T9 Arg2:T49	
T98	Quantifier_or_Qualifier 289 297	avanzado
#82	AnnotatorNotes T98	C0205179; Advanced phase; Qualitative Concept | C1522484; metastatic qualifier; Functional Concept
R24	Has_Quantifier_or_Qualifier Arg1:T9 Arg2:T98	
T99	Quantifier_or_Qualifier 612 620	avanzado
#83	AnnotatorNotes T99	C0205179; Advanced phase; Qualitative Concept | C1522484; metastatic qualifier; Functional Concept
R25	Has_Quantifier_or_Qualifier Arg1:T18 Arg2:T99	
R26	Before Arg1:T18 Arg2:T53	
R27	Location_of Arg1:T51 Arg2:T18	
R28	Location_of Arg1:T84 Arg2:T18	
R29	Location_of Arg1:T54 Arg2:T20	
R30	Location_of Arg1:T91 Arg2:T20	
T100	Quantifier_or_Qualifier 732 740	avanzado
#84	AnnotatorNotes T100	C0205179; Advanced phase; Qualitative Concept | C1522484; metastatic qualifier; Functional Concept
R31	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T100	
R32	Before Arg1:T20 Arg2:T56	
R33	Used_for Arg1:T50 Arg2:T11	
R34	Combined_with Arg1:T50 Arg2:T12	
R35	Combined_with Arg1:T12 Arg2:T13	
R36	Used_for Arg1:T15 Arg2:T14	
R37	Combined_with Arg1:T15 Arg2:T16	
R38	Combined_with Arg1:T16 Arg2:T17	
R39	Has_Age Arg1:T67 Arg2:T68	
T101	CONC 812 829	Esperanza de vida
#85	AnnotatorNotes T101	C0023671; Life Expectancy; Group Attribute
R40	Has_Duration_or_Interval Arg1:T101 Arg2:T69	
R41	Location_of Arg1:T92 Arg2:T21	
R43	Experiences Arg1:T70 Arg2:T21	
R44	Experiences Arg1:T70 Arg2:T95	
R45	Experiences Arg1:T71 Arg2:T22	
R46	Location_of Arg1:T93 Arg2:T22	
R47	Before Arg1:T22 Arg2:T57	
R48	Experiences Arg1:T71 Arg2:T57	
T102	Quantifier_or_Qualifier 980 988	avanzado
#86	AnnotatorNotes T102	C0205179; Advanced phase; Qualitative Concept | C1522484; metastatic qualifier; Functional Concept
R49	Has_Quantifier_or_Qualifier Arg1:T22 Arg2:T102	
T103	Quantifier_or_Qualifier 1007 1025	estadios IIIB o IV
R50	Has_Quantifier_or_Qualifier Arg1:T22 Arg2:T103	
R51	Experiences Arg1:T71 Arg2:T23	
R52	Experiences Arg1:T71 Arg2:T24	
T104	PROC 1125 1134	selección
#87	AnnotatorNotes T104	C0242802; Patient Selection; Research Activity
R53	Overlap Arg1:T22 Arg2:T104	
R54	Overlap Arg1:T57 Arg2:T104	
T105	Observation 1155 1165	participar
#88	AnnotatorNotes T105	C1278516; Patient participation status; Finding
R55	Location_of Arg1:T94 Arg2:T25	
R56	Experiences Arg1:T76 Arg2:T25	
T106	Observation 1223 1234	recidivante
#89	AnnotatorNotes T106	C2825055; Recurrence (disease attribute); Pathologic Function
R57	Has_Quantifier_or_Qualifier Arg1:T25 Arg2:T106	
R58	After Arg1:T106 Arg2:T26	
R60	Experiences Arg1:T76 Arg2:T26	
R61	Experiences Arg1:T76 Arg2:T27	
R62	Experiences Arg1:T76 Arg2:T28	
T107	Quantifier_or_Qualifier 1376 1386	al menos 1
R63	Has_Quantifier_or_Qualifier Arg1:T29 Arg2:T107	
R64	Causes Arg1:T30 Arg2:T29	
R65	Experiences Arg1:T79 Arg2:T29	
R66	Experiences Arg1:T79 Arg2:T30	
T108	Quantifier_or_Qualifier 1394 1408	unidimensional
R68	Has_Quantifier_or_Qualifier Arg1:T29 Arg2:T108	
T109	CONC 1463 1493	criterios RECIST (versión 1.1)
#90	AnnotatorNotes T109	C4086827; Response Evaluation Criteria in Solid Tumors Version 1.1; Intellectual Product
R69	Experiences Arg1:T80 Arg2:T33	
R70	Causes Arg1:T34 Arg2:T33	
R71	Causes Arg1:T35 Arg2:T33	
R72	Causes Arg1:T36 Arg2:T33	
R73	Causes Arg1:T37 Arg2:T33	
R74	Causes Arg1:T59 Arg2:T38	
R75	Experiences Arg1:T81 Arg2:T38	
R76	Experiences Arg1:T82 Arg2:T39	
T110	Quantifier_or_Qualifier 1796 1805	grado ≥ 2
R77	Has_Quantifier_or_Qualifier Arg1:T39 Arg2:T110	
R78	Experiences Arg1:T83 Arg2:T40	
R79	Location_of Arg1:T72 Arg2:T40	
R80	Experiences Arg1:T83 Arg2:T31	
R81	Location_of Arg1:T85 Arg2:T31	
R82	Experiences Arg1:T83 Arg2:T60	
R83	Experiences Arg1:T83 Arg2:T32	
R84	Experiences Arg1:T88 Arg2:T41	
R85	Experiences Arg1:T88 Arg2:T42	
R86	Experiences Arg1:T88 Arg2:T43	
R87	Experiences Arg1:T88 Arg2:T44	
R88	Location_of Arg1:T86 Arg2:T60	
T111	GENE 1963 1970	exón 21
R89	Location_of Arg1:T111 Arg2:T32	
T112	Observation 1977 1991;2001 2012	reordenamiento del gen ALK
#91	AnnotatorNotes T112	C4068350; ALK Gene Rearrangement; Finding
R90	Location_of Arg1:T87 Arg2:T112	
R91	Experiences Arg1:T83 Arg2:T112	
R92	Before Arg1:T26 Arg2:T105	
R93	Experiences Arg1:T79 Arg2:T58	
R42	Overlap Arg1:T31 Arg2:T60	
#92	AnnotatorNotes T96	C1880198; Cure (remedy); Conceptual Entity
#93	AnnotatorNotes T97	C1880198; Cure (remedy); Conceptual Entity
A21	Experiencer T67 Patient
A22	Experiencer T70 Patient
A23	Experiencer T71 Patient
A24	Experiencer T76 Patient
A25	Experiencer T79 Patient
A26	Experiencer T80 Patient
A27	Experiencer T81 Patient
A28	Experiencer T82 Patient
A29	Experiencer T83 Patient
A30	Experiencer T88 Patient
